MENU
CLOSE
At Conexeu, we are developing CXU™ as a next-generation collagen-based ECM platform for tissue regeneration, designed to move beyond static fillers and more closely reflect the biology of the body’s native extracellular matrix. By combining immediate structural support with the potential for tissue in-growth and longer-term integration, our goal is to create a more regenerative approach to soft-tissue restoration.
One platform, one formula, one device for broad potential use across a range of human and animal applications.
How CXU Works
How CXU Works
Starts as a flowable liquid
At room temperature, CXU flows to fill voids where tissue has been lost, maintaining continuous contact for seamless adaptation in the body’s tissue spaces.9
How CXU Works
Set as a gel
After ~10 minutes at 37°C (body temperature), CXU transforms into a gel that provides volume and creates a stable interface.9
How CXU Works
Designed to enable functional tissue regeneration
CXU is being developed to unlock the regenerative potential of native tissues, designed to provide a temporary structural ECM framework that supports the body's own repair and regenerative processes from within.
In preclinical models, investigators report cell presence and infiltration within and at the CXU scaffold-tissue interface, consistent with a scaffold that supports host integration as part of normal tissue repair.3,4,5,7
Published in vivo studies report findings consistent with vascular ingrowth and remodeling in the presence of the scaffold, supporting the concept that CXU may serve as a structural framework allowing for tissue restoration.3,4,7
Preclinical evaluations report a reduced inflammatory profile in the presence of the CXU scaffold, consistent with a material that supports organized repair rather than a prolonged inflammatory phase.3,4,5,7
The scaffold is intended to be gradually resorbed through endogenous processes, leaving behind host tissue rather than a permanent foreign structure.1,2,4,5,7
Conexeu is not simply repairing tissue. We are building a new blueprint for regeneration, one that is disciplined, intentional and grounded in more than a decade of research.
Developed over 10 years at a leading Canadian University.
Conexeu owns the right, title, and interest to the patents worldwide.
Acta Biomaterialia, Advances in Wound Care, Biomedical Materials, Canadian Journal of Diabetes, Experimental Dermatology, Gels, Journal of Burn Care, Tissue Engineering, Transplantation
*All cited studies are preclinical. Findings have not been validated in human clinical trials and are not predictive of clinical outcomes.
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.
